These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32589369)

  • 1. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
    Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
    ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of growth differentiation factor-15 in heart failure among whole ejection fraction phenotypes.
    Lyu L; Xu J; Xv C; Xiao H; Liu Z; He Y; Gao W; Hao B; Liu H
    ESC Heart Fail; 2024 Aug; 11(4):2295-2304. PubMed ID: 38641904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction.
    Yin D; Yan X; Bai X; Tian A; Gao Y; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1025-1034. PubMed ID: 36519216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
    Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.
    Savarese G; Orsini N; Hage C; Dahlström U; Vedin O; Rosano GMC; Lund LH
    J Card Fail; 2018 Jun; 24(6):365-374. PubMed ID: 29597053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
    Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure.
    Liang L; Huang L; Zhao X; Zhao L; Tian P; Huang B; Feng J; Zhang J; Zhang Y
    Clin Cardiol; 2022 Jul; 45(7):802-813. PubMed ID: 35621296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
    Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
    [No Abstract]   [Full Text] [Related]  

  • 11. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
    Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
    Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
    [No Abstract]   [Full Text] [Related]  

  • 12. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
    Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
    Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of predictive value of NT-proBNP, sST2 and MMPs in heart failure patients with different ejection fractions.
    Pan W; Yang D; Yu P; Yu H
    BMC Cardiovasc Disord; 2020 Apr; 20(1):208. PubMed ID: 32354356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
    Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
    Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum fibroblast growth factor 21 levels were related to the prognosis and ventricular remodeling of heart failure patients with mildly reduced and reduced ejection fraction.
    Fan L; Gu L; Yao Y; Ma G
    Perfusion; 2024 Mar; 39(2):285-293. PubMed ID: 36321746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure.
    Li J; Cui Y; Huang A; Li Q; Jia W; Liu K; Qi X
    Med Sci Monit; 2018 Jul; 24():4992-4999. PubMed ID: 30019695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF.
    Savarese G; Orsini N; Hage C; Vedin O; Cosentino F; Rosano GMC; Dahlström U; Lund LH
    JACC Heart Fail; 2018 Mar; 6(3):246-256. PubMed ID: 29428439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study.
    Sharma A; Stevens SR; Lucas J; Fiuzat M; Adams KF; Whellan DJ; Donahue MP; Kitzman DW; Piña IL; Zannad F; Kraus WE; O'Connor CM; Felker GM
    JACC Heart Fail; 2017 Oct; 5(10):724-734. PubMed ID: 28958347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.
    Hao J; Cheang I; Zhang L; Wang K; Wang HM; Wu QY; Zhou YL; Zhou F; Xu DJ; Zhang HF; Yao WM; Li XL
    Chin Med J (Engl); 2019 Oct; 132(19):2278-2285. PubMed ID: 31567379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.